While Ascendis Pharma A/S ADR has overperformed by 0.56%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ASND rose by 33.01%, with highs and lows ranging from $161.00 to $64.33, whereas the simple moving average jumped by 41.78% in the last 200 days.
On December 20, 2023, Jefferies started tracking Ascendis Pharma A/S ADR (NASDAQ: ASND) recommending Buy. Morgan Stanley April 04, 2023d the rating to Equal-Weight on April 04, 2023, and set its price target from $151 to $108. Credit Suisse April 03, 2023d its ‘Outperform’ rating to ‘Neutral’ for ASND, as published in its report on April 03, 2023. Goldman’s report from October 20, 2022 suggests a price prediction of $174 for ASND shares, giving the stock a ‘Buy’ rating. Berenberg also rated the stock as ‘Buy’.
Analysis of Ascendis Pharma A/S ADR (ASND)
Further, the quarter-over-quarter increase in sales is 534.07%, showing a positive trend in the upcoming months.
To gain a thorough understanding of Ascendis Pharma A/S ADR’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -867.62% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 2.50, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and ASND is recording an average volume of 582.53K. On a monthly basis, the volatility of the stock is set at 4.07%, whereas on a weekly basis, it is put at 3.68%, with a loss of -6.60% over the past seven days. Furthermore, long-term investors anticipate a median target price of $175.38, showing growth from the present price of $147.76, which can serve as yet another indication of whether ASND is worth investing in or should be passed over.
How Do You Analyze Ascendis Pharma A/S ADR Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 1.59%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 106.18% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
ASND shares are owned by institutional investors to the tune of 106.18% at present.
